| AKT | Protein kinase B |
| APC | Antigen presenting cell |
| APE1 | Apurinic/apyrimidinic endonuclease 1 |
| BAD | BCL2 associated agonist of cell death |
| BRAF | v-Raf murine sarcoma viral oncogene homolog B |
| CAFs | Cancer-associated fibroblasts |
| CAR-T | Chimeric antigen receptor T-cells |
| CCL2 | C-C Motif Chemokine Ligand 2 |
| CCL-22 | C-C motif chemokine 22 |
| CD | Cluster differentiation |
| CRAF | v-raf1 murine leukemia viral oncogene homolog 1 |
| CTL | Cytotoxic lymphocytes |
| CTLA-4 | cytotoxic T-lymphocyte-associated protein 4 |
| CXCL-2 | CXC chemokine ligand 2 |
| CXCL5 | CXC motif chemokine 5 |
| DCs | Dendritic cells |
| DNAM-1 | DNAX accessory molecule-1 |
| ECM | Extracellular matrix |
| EMT | Epithelial mesenchymal transition |
| ErbB3 | V-erb-b2 avian erythroblastic leukemia viral oncogene homolog3 |
| ERK | Extracellular signal-regulated kinase |
| FAK | Focal adhesion kinase |
| FAP | Fibroblast activation protein |
| FcγR | Fragment crystallizable-gamma receptor |
| FDA | Food and Drug Administration |
| FGF 2-19 | Fibroblast growth factor 2-19 |
| FGFR-3 | Fibroblast growth factor receptor 3 |
| FSP1 | Fibroblast specific protein 1 |
| GSK3β | Glycogen synthase kinase 3 beta |
| Gp | Glycoprotein |
| HER3 | V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3 |
| HGF | Hepatocyte growth factor |
| ICIs | Immune checkpoint inhibitors |
| IDO | Indoleamine-2,3-dioxygenase |
| Ig | Immunoglobulin |
| IGF-1 | Insulin-like growth factor 1 |
| IGF-1R | Insulin-like growth factor receptor 1 |
| IL | Interleukin |
| ITIM | Immunoreceptor tyrosine-based inhibition motif |
| KIT | v-kit Hardy–Zuckerman 4 feline sarcoma viral oncogene homolog |
| LIPA | Lysosomal acid lipase A |
| MAPK | Mitogen-activated protein kinase |
| MCL-1 | Myeloid leukemia cell protein 1 |
| MCH-I | Major histocompatibility complex 1 |
| MDSCs | Myeloid-derived suppressor cells |
| MEK | Mitogen-activated protein kinase kinase |
| MET | Mesenchymal epithelial transition receptor |
| MHC | Major histocompatibility complex |
| miRNA | microRNA |
| MITF | Microphthalmia-associated transcription factor |
| MMPs | Matrix metalloproteinases |
| NFkB | Nuclear factor kappa-light-chain-enhancer of activated B cells |
| NGS | Next-generation sequencing |
| NK | Natural killer |
| NKG2D | Natural killer group 2D |
| NRAS | Neuroblastoma RAS viral oncogene homolog |
| NRG-1 | Neuregulin 1 |
| ORR | Objective response rate |
| OS | Overall survival |
| PBMC | Peripheral blood mononuclear cells |
| PD-1 | Programmed cell death protein 1 |
| PDGFR | Platelet-derived growth factor receptor |
| PDL-1/2 | Programmed death ligands 1/2 |
| PI3K | Phosphatidyl Inositol 3-kinase |
| PFS | Progression-free survival |
| PTEN | Phosphatase and tensin homolog on chromosome 10 |
| ROS | Reactive oxygen species |
| RTK | Tyrosine kinase receptor |
| sFRP2 | Secreted frizzled-related protein 2 |
| STAT | Signal transducer and activator of transcription |
| SRC | V-src sarcoma (Schmidt–Ruppin A-2) viral oncogene homolog avian |
| TAB | Tumor-associated B cells |
| TAMs | Tumor-associated macrophages |
| TCF7 | Transcription factor 7 |
| TGF-β | Transforming growth factor β |
| TIGIT | T cell Ig and ITIM domain |
| TIL | Tumor-infiltrating lymphocytes |
| Tim3 | Immunoglobulin and mucin domain-containing molecule 3 |
| TME | Tumor microenvironment |
| TNFα | Tumor necrosis factor α |
| TRAF6 | Tumor necrosis factor receptor-associated factor 6 |
| Tregs | Regulatory T cells |
| VEGF | Vascular endothelial growth factor |
| VISTA | V-domain Ig suppressor of T cell activation |
| Wnt | wingless type MMTV integration site family member |
| α-SMA | α smooth muscle actin |